← The Procter & Gamble Company

PG · Forward model · Bear case

The Bear case, 20 quarters out

Model as of

Each segment is projected from its own operating driver, rolled up into consolidated cash flow, and discounted back to a fair value per share. The assumptions below are editable — change them and every number on this page moves with them.

Every revenue line here is a reportable segment P&G discloses, not an apportionment. The five operating segments plus Corporate sum to reported consolidated net sales in all twenty quarters, with a largest residual of $2m on $21bn - P&G's own rounding in its $-million segment table. Sixteen of the twenty quarters per line are read from a filed segment table; the four April-June quarters are derived as fiscal-year segment total less the disclosed nine-month segment column and are marked estimated, and the most recent of them is independently confirmed line by line in the Q4 fiscal 2026 8-K. NOT disclosed and therefore not modelled: any dollar split of a segment into its named categories - P&G publishes only whole-percent-of-company shares such as 'Fabric Care 23%' - any geographic split below US and international totals, any unit, volume or household count, and any allocation of restructuring cost to a segment. Because P&G discloses no operational level for any segment, every vertical uses the growth driver; the volume, currency, price, mix and acquisition percentages the company does publish are evidence for the rate, not a level to model. Segment EBITDA margins are fiscal 2026 GAAP figures - (segment earnings before income taxes + segment depreciation and amortisation) / segment net sales - because segment D&A is disclosed annually only; the June quarter itself was restructuring-depressed at 18.6% GAAP operating margin against 19.5% core. The whole of the restructuring programme, the interest line and the unallocated overhead sit in the Corporate vertical, so corporate.overheadPctRevenue is zero to avoid counting them twice. The 20% tax rate is P&G's guided fiscal 2027 core effective rate. Consensus EPS for this company is a core figure and must never be paired with the site's stored GAAP EPS: the June quarter's $1.43 core beat a $1.41-$1.42 street number, while GAAP was $1.26.

PG forward model
Horizon
Fair value per share $100.64 −31% against $145.28
Terminal-year revenue $88.47B last four projected quarters
Enterprise value $258.12B $61.52B explicit + $196.60B terminal

Guidance is not reached and the multiple goes with it. The June quarter printed 0% organic growth with volume, price and mix all flat, Baby, Feminine & Family Care fell 2% organic, and Health Care's Oral Care lost volume in both North America and Greater China. Against that, fiscal 2027 carries a disclosed ~$1bn after-tax cost headwind worth $0.56 a share, most of it in the first half, and the CFO has already said first-quarter EPS will be 'down 5% or more'. The 0.25pp a quarter this case removes from every line is itself disclosed arithmetic: roughly 0.15pp of the trailing rate is the fiscal 2026 currency tailwind that guidance sets to zero, and about 0.10pp is the 30 to 50 basis points of brand, product form and go-to-market discontinuations P&G has put inside its own organic guidance. Margins give back 100bp for the reinvestment step-up and the exit falls to 12x, roughly the 2018 staples de-rating. Fiscal 2027 net sales land at $86.90bn, 0.15% below fiscal 2026 and below the guided floor of $87.90bn, and fair value is $100.64.

PG REVENUE MODEL

Latest: $21.67B (2031Q2E)

Period Value
2021Q3 $20.34B
2021Q4 $20.95B
2022Q1 $19.38B
2022Q2 $19.52B
2022Q3 $20.61B
2022Q4 $20.77B
2023Q1 $20.07B
2023Q2 $20.55B
2023Q3 $21.87B
2023Q4 $21.44B
2024Q1 $20.20B
2024Q2 $20.53B
2024Q3 $21.74B
2024Q4 $21.88B
2025Q1 $19.78B
2025Q2 $20.89B
2025Q3 $22.39B
2025Q4 $22.21B
2026Q1 $21.23B
2026Q2 $21.20B
2026Q3E $22.41B
2026Q4E $22.23B
2027Q1E $20.96B
2027Q2E $21.29B
2027Q3E $22.51B
2027Q4E $22.33B
2028Q1E $21.05B
2028Q2E $21.38B
2028Q3E $22.61B
2028Q4E $22.43B
2029Q1E $21.14B
2029Q2E $21.48B
2029Q3E $22.72B
2029Q4E $22.53B
2030Q1E $21.23B
2030Q2E $21.57B
2030Q3E $22.83B
2030Q4E $22.64B
2031Q1E $21.33B
2031Q2E $21.67B
Scenarios

Where each case comes from

Valuation

From cash flow to fair value

The published model, discounted at 7.0% a year with an exit multiple of 12.0x on EBITDA. The horizon and sliders above do not change this walk.

Present value of free cash flow, 20 quarters$61.52B
Terminal-year revenue$88.47B
Terminal-year EBITDA$22.98B
Exit multiple, on EBITDA12.0x
Terminal value$275.75B
Discounted at 7.0% a year, terminal value becomes$196.60B
Share of enterprise value from the terminal76%
Enterprise value$258.12B
Net cash−$24.20B
Equity value$233.93B
Shares2.32B
Fair value per share$100.64
Against the deployed price of $145.28, as of −31%

P&G trades at 15.77x trailing EBITDA: an enterprise value of $361.2bn - $337.0bn of market capitalisation on 2,324,433,060 shares at $145.00, plus $24.2bn of net debt - over fiscal 2026 EBITDA of $22,908m, which is reported operating income of $19,748m plus $3,160m of depreciation and amortisation. That is 21.9x trailing GAAP EPS of $6.62 and 20.7x the $7.00 core guidance midpoint; StockAnalysis independently shows 21.89x and 20.75x. The base case exits at 15.0x, a shade below today's rating, because a terminal multiple should not assume the current one survives five years on a company whose June-quarter organic sales growth was zero with volume, price and mix all flat. The 7.0% discount rate is a staples cost of capital for an A-rated issuer on a 3.0% dividend yield; P&G discloses no WACC. This one assumption dominates: $267.3bn of the base case's $333.4bn enterprise value, 80%, is the discounted exit multiple, and one turn of EBITDA on the $24.99bn terminal year is $17.8bn once discounted, about $7.66 a share.

Read the other way round: at $145.28 the market is paying 18.3x terminal-year EBITDA, holding every other assumption on this page fixed. That is the number to argue about.

Quarter by quarter

The projected path

The published model's 20 quarters. The horizon and sliders above do not change this table.

Quarter BeautyGroomingHealth CareFabric & Home CareBaby, Feminine & Family CareCorporate Revenue YoY EBITDA Capex FCF R40 PV of FCF
2026 Q3E $4.37B$1.77B$3.18B$7.76B$5.04B$292M $22.41B 0% $5.68B $1.13B $3.64B +16 $3.58B
2026 Q4E $4.21B$1.77B$3.34B$7.59B$5.03B$292M $22.23B 0% $5.69B $1.12B $3.66B +17 $3.53B
2027 Q1E $3.85B$1.56B$3.00B$7.25B$5.03B$292M $20.96B −1% $5.39B $1.07B $3.46B +15 $3.29B
2027 Q2E $4.07B$1.70B$2.77B$7.44B$5.02B$292M $21.29B 0% $5.50B $1.08B $3.53B +17 $3.30B
2027 Q3E $4.47B$1.77B$3.19B$7.77B$5.01B$292M $22.51B 0% $5.83B $1.13B $3.76B +17 $3.45B
2027 Q4E $4.30B$1.78B$3.35B$7.60B$5.00B$292M $22.33B 0% $5.80B $1.13B $3.74B +17 $3.38B
2028 Q1E $3.94B$1.56B$3.01B$7.26B$5.00B$292M $21.05B 0% $5.46B $1.07B $3.52B +17 $3.12B
2028 Q2E $4.16B$1.71B$2.79B$7.45B$4.99B$292M $21.38B 0% $5.55B $1.08B $3.58B +17 $3.12B
2028 Q3E $4.57B$1.78B$3.21B$7.78B$4.98B$292M $22.61B 0% $5.87B $1.13B $3.79B +17 $3.26B
2028 Q4E $4.40B$1.78B$3.37B$7.61B$4.97B$292M $22.43B 0% $5.84B $1.13B $3.77B +17 $3.18B
2029 Q1E $4.03B$1.56B$3.03B$7.26B$4.97B$292M $21.14B 0% $5.49B $1.07B $3.54B +17 $2.94B
2029 Q2E $4.25B$1.71B$2.80B$7.46B$4.96B$292M $21.48B 0% $5.58B $1.08B $3.60B +17 $2.94B
2029 Q3E $4.67B$1.78B$3.23B$7.79B$4.95B$292M $22.72B 0% $5.90B $1.13B $3.81B +17 $3.06B
2029 Q4E $4.50B$1.79B$3.39B$7.62B$4.94B$292M $22.53B 0% $5.86B $1.13B $3.79B +17 $2.99B
2030 Q1E $4.12B$1.57B$3.04B$7.27B$4.94B$292M $21.23B 0% $5.52B $1.07B $3.56B +17 $2.76B
2030 Q2E $4.35B$1.72B$2.82B$7.47B$4.93B$292M $21.57B 0% $5.60B $1.09B $3.61B +17 $2.76B
2030 Q3E $4.78B$1.79B$3.24B$7.80B$4.92B$292M $22.83B 0% $5.93B $1.14B $3.83B +17 $2.88B
2030 Q4E $4.61B$1.79B$3.41B$7.63B$4.91B$292M $22.64B 0% $5.89B $1.13B $3.81B +17 $2.81B
2031 Q1E $4.21B$1.57B$3.06B$7.28B$4.91B$292M $21.33B 0% $5.54B $1.07B $3.57B +17 $2.59B
2031 Q2E $4.45B$1.72B$2.83B$7.48B$4.90B$292M $21.67B 0% $5.63B $1.09B $3.63B +17 $2.59B

Every row is projected. A year-over-year change is shown only where the quarter it compares against exists — an em dash means there is no comparable quarter, not a flat year.

Track record

Model revisions

Assumptions are marked to reality as each quarter prints. Every change is appended here, with the fair value the model produced at the time, so the model's own history stays visible.

DateFair value thenNote
2026-08-27 $133.02 First published model. Built on the fiscal 2026 fourth quarter reported 29 July 2026: six disclosed segment lines across twenty quarters, four-factor seasonality on the four segments where the derived shape beats its own window-to-window spread, and a base case pinned to trailing deseasonalised growth rather than to guidance.